Inactive Instrument

Viatar CTC Solutions Inc. Share Price Other OTC

Equities

VRTT

US92556J1034

Advanced Medical Equipment & Technology

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Dynamic Chart
Viatar CTC Solutions Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter Ended June 30, 2016 CI
Viatar CTC Solutions Inc. Announces Executive Appointments CI
Viatar CTC Solutions Inc. Announces Financial Results for the First Quarter Ended March 31, 2016 CI
Viatar CTC Solutions, Inc. Reports Unaudited Consolidated Earnings Results for the Full Year Ended December 31, 2015 CI
Viatar CTC Solutions Inc. announced that it has received $0.5 million in funding CI
Viatar CTC Solutions Inc. announced that it expects to receive $0.5 million in funding. CI
Viatar CTC Solutions Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015 CI
Viatar CTC Solutions Inc. announced that it has received $0.23 million in funding. CI
Viatar CTC Solutions Inc. announced that it has received $1 million in funding. CI
Viatar CTC Solutions Inc. announced that it expects to receive $1 million in funding. CI
Viatar CTC Solutions Inc. announced that it expects to receive $0.23 million in funding. CI
Viatar CTC Solutions, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2015 CI
Viatar CTC Solutions Inc. announced that it has received $0.17 million in funding. CI
Viatar CTC Solutions Inc. announced that it expects to receive $0.08 million in funding. CI
Viatar CTC Solutions Inc. Auditor Raises 'Going Concern' Doubt CI
More news
Managers TitleAgeSince
Chief Executive Officer 69 18/07/18
Chief Tech/Sci/R&D Officer 61 01/12/01
Members of the board TitleAgeSince
Chief Executive Officer 69 18/07/18
More insiders
Viatar CTC Solutions Inc., formerly Vizio Medical Devices LLC, is a medical technology company. The Company is focused on developing and marketing products to collect cancer cells for molecular diagnostics by others and as cancer therapy, both of which are based on the principle of removing blood-borne circulating tumor cells (CTCs). These CTCs detach from solid tumors and enter the bloodstream carrying the deoxyribonucleic acid (DNA) of the tumor and seeding new tumors. The Company is seeking to commercialize over two products, which utilizes its CTC removal technology, including Viatar Collection System for Molecular Analysis, which collects and purifies a quantity of CTCs from approximately 50 milliliters of blood as the front end for DNA sequencing and other genetic analysis technologies used primarily for research, and Viatar Therapeutic Oncopheresis System, which removes CTCs from a patient's blood as a cancer therapy for metastatic disease.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW